Stryker Corporation

▲ Bull Case

• ◆Switching costs deeply embedded: Mako-trained surgeons invested 100+ hours in workflow integration; 3,000+ installed bases create institutionalized training across hospitals and sales networks that competitors cannot easily displace
• ◆CT-based data moat widening with AI integration: 10-year proprietary 3D anatomical dataset from 2M+ procedures foundational for AI/ML surgical planning; competitors who chose CT-free workflows cannot retroactively generate data as AI becomes critical in 2027–2030
• ◆Mako Spine/Shoulder launches reset competitive clock in 2026: hospitals with existing Mako-Knee can add adjacent modules at lower cost with same trained surgeons; unlocks pull-through dynamics and extends TAM into new specialties

▼ Bear Case

• ◆Velys CT-free workflow wins on total-cost-of-ownership: eliminates ~$2K per-procedure CT cost and OR registration time; as hospitals consolidate, procurement leverage makes TCO binding constraint for routine high-volume knees
• ◆Next-tier hospital penetration targets smaller, price-sensitive customers: Stryker already placed Mako at highest-value sites (large academic centers); remaining universe is smaller and cost-conscious—natural CT-free buyer profile
• ◆AI-enabled CT-free systems could neutralize data moat faster: if MDT/JNJ leverage Caption AI or J&J Polymath to deliver CT-free + AI workflows in 2027–2028, proprietary data advantage erodes more rapidly than base case

“Central debate: Is Mako's 60%+ orthopaedic robotic-surgery share durable as MDT ROSA and JNJ Velys mature, or will competitive intensity compress SYK's premium multiple? Market at ~21x NTM pricing yes—compression incoming. Bull counter: (1) switching costs embedded via 3,000+ installs are durable, (2) CT-based dataset widens as AI becomes critical, (3) competitor gains come from new placements in cost-conscious segments, not displacements from quality-focused centers, (4) Spine/Shoulder reset competitive clock. Author weights bull 55% / bear 45%, favoring durability thesis but acknowledging genuine pressure.”

• ◆Q2 2026 earnings (August 2026) — simultaneous confirmation of cyberattack recovery + first read on Mako Spine/Shoulder procedure volume; highest-information event of year
• ◆Mako Spine full commercial launch with H2 2026 procedure volume data — validates TAM expansion and pull-through dynamics in adjacent specialty
• ◆Mako Shoulder full launch (H1–H2 2026) — extends platform to smaller but credible market with validated surgeon adoption curve
• ◆Inari Medical integration trajectory (Q2–Q3 2026) — confirm revenue acceleration via Stryker distribution leverage targeting 25%+ organic growth post-integration
• ◆CEO succession formal announcement — eventual Lobo retirement timing clarifies governance and removes uncertainty premium

• ◆Cyberattack-2 (Q3–Q4 2026 watch window; elevated post-incident) — repeat attack invalidates recovery thesis, promotes severe-bear scenario from 5% to 15%+ probability, drives multi-quarter multiple compression
• ◆Tariff escalation beyond current $200M annual headwind — active policy uncertainty; escalation compresses operating margins and potentially triggers guidance cuts
• ◆J&J Velys/MDT ROSA competitive share gains (medium probability) — quality-segmented market limits displacement risk but high-volume routine knee mix shifts could compress Mako growth trajectory
• ◆FDA Mako recall or regulatory hold (very low probability, very high impact) — thesis-breaking scenario requiring complete reset
• ◆Inari Medical integration disappointment (low-medium probability, medium impact) — underperformance on revenue/margin assumptions would reduce FY2027–FY2028 EPS by $0.30–$0.50 per share